People diagnosed with locally advanced/metastatic HER2-positive gastroesophageal adenocarcinoma continue to face limited treatment options with the need to improve outcomes. Discover why innovation in the first-line setting remains essential to improving care.

Epilepsy is one of the most common neurological diseases in the world. While many treatments are available, there remains a significant unmet need among adult and pediatric patients who experience treatment-resistant seizures. Read more about how we are continuing to shine a light on the real-world burden associated with living with rare, treatment-resistant epileptic conditions.

For years, relapse after initial therapy has defined the outlook for people with extensive-stage small cell lung cancer (ES-SCLC). The FDA approval of a first-line maintenance combination regimen marks an important step forward, building on past progress and creating the possibility of longer-lasting benefit for patients and families.

Our teams at Jazz recognize the importance of collaborating with and learning from the sleep community. Our ongoing data generation is fueled by insights from people living with narcolepsy and idiopathic hypersomnia and expand our understanding of the realities of people living with these conditions.

We are focused on advancing innovation where it matters most for people facing some of the toughest cancers. Explore how our commitment to high-unmet need diseases like extensive-stage small cell lung cancer (ES-SCLC) is helping to drive meaningful progress in cancer care.

Watch Sarah McMahon, Senior Vice President, Sleep Franchise Head, highlight the importance of recognizing the realities of people living with sleep conditions to inform innovation and care.